Press Releases

All Releases

Alcobra Announces Leadership Update

Dr. Yaron Daniely to Step Down as Chief Executive Officer, Effective May 31, 2017 David Baker Named Interim Chief Executive Officer Dr. Daniely to Remain on Board of Directors and be Appointed Chairman TEL AVIV, Israel, May 15, 2017 (GLOBE N...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group

TEL AVIV, Israel, May 05, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that it has reached an agreement (the "Agreement") with Brosh Capital L.P. and certain of its affiliates (th...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Provides Update on Request for Extraordinary General Meeting

Brosh Capital's Request Does Not Comply With Alcobra's Articles of Association Company Addresses Brosh Capital's Misinformed Views   TEL AVIV, Israel, April 05, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the deve...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Ltd. to Participate in Upcoming Healthcare Conferences

TEL AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced that management will participate in two upcoming investor healthcare conferences during March. ...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra to Host Investor Forum and Webcast on March 28 in New York City

TEL AVIV, Israel, March 01, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced that it will host an investor forum on Tuesday, March 28, 2017 from 8:00-9:30 a.m. EST in ...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Corporate Update

Conference Call & Webcast February 15th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time TEL AVIV, Israel, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat CNS and cognitive disorders, today announced...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Ltd. to Release Fiscal 2016 Financial Results and Participate at the BIO CEO & Investor Conference in New York

TEL AVIV, Israel, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat CNS and cognitive disorders, today announced that it will report its financial results for the year ended December 31, 2016 on Wednesday, February 15, at 8:30 am ...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD

Pre-IND meeting held on Alcobra's proprietary Abuse-Deterrent, Amphetamine Immediate Release (ADAIR) product candidate.Meeting defined a 505(b)(2) development path, to be funded with existing cash balance, and targe...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Reports Phase 3 Clinical Trial of MDX in Adults with ADHD Missed Primary Endpoint

TEL AVIV, Israel, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today reported the top-line results from ME...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Provides Update on Recent FDA Meeting and Path Forward for MDX Clinical Development Program

- Alcobra and FDA agree on review of available data from the Phase 3 MEASURE study in a future NDA submission- Top-line results from the MEASURE study to be reported in the coming weeks- FDA to modify Clinical Hold from Full to Partial to allow the conduct of a Phase I safety study- Management to hold a confere...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Updates on Recent FDA Meeting

TEL AVIV, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that it recently held a productive face-...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Announces Third Quarter 2016 Financial Results and Provides Corporate Update

Conference Call & Webcast November 15th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time TEL AVIV, Israel, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, incl...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Ltd. to Participate in Upcoming Healthcare Conferences

TEL AVIV, Israel, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that management will participate in sever...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Ltd. to Release Third Quarter Financial Results and Host Corporate Update Conference Call & Webcast on November 15

TEL AVIV, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its fina...

Add to Briefcase

PDF  |  Continue Reading →

Update from Alcobra on Recent FDA Communications

TEL AVIV, Israel, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that it has received the written full cl...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study

TEL AVIV, Israel, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it has received verbal notice fr...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Announces Second Quarter 2016 Financial Results and Provides Corporate Update

TEL AVIV, Israel, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced financial results for the three and six ...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Ltd. to Release Second Quarter Financial Results and Host Corporate Update Conference Call & Webcast on Tuesday, August 30

Tel Aviv, Israel, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial resul...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome

TEL AVIV, Israel, July 19, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that the European Commission...

Add to Briefcase

PDF  |  Continue Reading →

Alcobra Ltd. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

TEL AVIV, Israel, July 05, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced that it will be presenting...

Add to Briefcase

PDF  |  Continue Reading →

Add to Briefcase = add release to Briefcase